SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Altamira Therapeutics

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% in Altamira Therapeutics Ltd., holding 478,547 common shares as of December 31, 2024.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as 'Reporting Persons,' have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Altamira Therapeutics Ltd.
• As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 478,547 common shares of Altamira Therapeutics Ltd.
• This ownership represents 9.99% of the total outstanding common shares of Altamira Therapeutics Ltd., par value USD 0.002 per share.
• Armistice Capital, LLC, a Delaware entity, is identified as an investment adviser and other organization, acting as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares.
• Steven Boyd, a U.S. citizen, is identified as an individual and parent holding company, serving as the managing member of Armistice Capital, LLC.
• Both Armistice Capital, LLC and Steven Boyd share voting and dispositive power over all 478,547 shares, with no sole voting or dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This document is a factual report of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment regarding the issuer's performance or future prospects. It simply discloses a significant stake.

Positives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, have disclosed a substantial 9.99% stake in Altamira Therapeutics Ltd., potentially signaling confidence in the company's prospects.
• The filing explicitly states that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control, suggesting a passive investment approach.

Negatives

• The document, being a beneficial ownership report, does not contain information that would typically be categorized as 'negatives' regarding the issuer's operational performance or financial health.

Risks

• The document does not detail specific risks related to Altamira Therapeutics Ltd.'s operations, financial condition, or future prospects. It is solely a disclosure of beneficial ownership.

Future Outlook

NA

Industry Context

This Schedule 13G filing indicates a significant passive investment by Armistice Capital, LLC, an investment adviser, and Steven Boyd, in Altamira Therapeutics Ltd. Such filings are common in the investment industry, providing transparency into large ownership stakes held by institutional investors. They can signal investor interest in a company within its sector, though they do not provide operational or strategic insights into the company itself.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.99% stake by an institutional investor like Armistice Capital and its managing member, Steven Boyd, could be viewed positively by other shareholders as it signals institutional confidence and potentially increased liquidity or stability for the stock.
• Company Management: Awareness of a large institutional holder may influence management's strategic decisions, though the filing explicitly states the stake is not for control purposes.

Key Dates

Keywords

Altamira Therapeutics Ltd., Armistice Capital LLC, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Shares, Institutional Investor, Equity Stake